Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, and electroporated with clustered regularly interspaced short palindromic repeats (CRISPR) guide RNA to disrupt expression of endogenous hematopoietic progenitor kinase 1 (HPK1), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the autologous CRISPR-edited anti-CD19 CAR T-cells XYF19 recognize and bind to CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. Disrupting the expression of HPK1 may enhance immune response and autoimmunity. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. HPK1 is a Ste20-like serine/threonine kinase that suppresses immune responses and autoimmunity.

**Synonyms:** - Autologous CRISPR-edited CD19-specific CAR-T Cells XYF19 - CAR-T Cells XYF19 - CRISPR (HPK1)-edited CD19-specific CAR-T Cells XYF19 - XYF 19 - XYF-19 - XYF19